{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T17:23:38Z","timestamp":1783963418512,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Delirium is a frequent complication in older patients admitted to emergency wards, leading to prolonged hospitalization and increased mortality. Although multicomponent interventions are recommended, the evidence for pharmacological prevention remains inconsistent. Protocol-Based Pharmacotherapy Management (PBPM) allows pharmacists to actively manage medications according to a pre-agreed protocol. This study aims to evaluate the efficacy and safety of an \u201cActive PBPM\u201d strategy for delirium prevention compared with that via a standard \u201cPassive PBPM\u201d strategy in elderly emergency patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, open-label, randomized controlled trial will target patients aged\u2009\u226565\u00a0years admitted to the general ward of the Department of Primary Care and Emergency Medicine from the emergency room. Eligible patients must have at least one risk factor (e.g., cognitive dysfunction, central nervous system disease). The patients will be randomized (1:1) into either the Active or Passive PBPM group. In the Active PBPM group, pharmacists will intervene to administer prophylactic medication for 3\u00a0days, starting on admission day 1. Patients capable of oral intake will receive ramelteon (8\u00a0mg) and lemborexant (5\u00a0mg) at bedtime. Patients unable to take oral medication will receive a blonanserin patch (20\u00a0mg) applied overnight (19:00\u201306:00). In the Passive PBPM group, pharmacological intervention will be performed only if insomnia occurs. The primary outcome will be the incidence of delirium diagnosed by a psychiatrist based on the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria, within the first 3\u00a0days. The secondary outcomes include delirium severity (Delirium Rating Scale-Revised-98), assessed by trained nurses, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study will determine whether pharmacist-led proactive pharmacological intervention (Active PBPM) reduces the incidence of delirium in high-risk older patients in acute care settings. The findings may establish a new standard of care for the prevention of delirium in emergency medicine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Japan Registry of Clinical Trials (jRCT) jRCTs051220122. Registered on November 25, 2022<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09781-6","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:04:23Z","timestamp":1779264263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preventive effects of active Protocol-Based Pharmacotherapy Management for delirium in general wards of emergency department (aPBPM trial): study protocol for a single-center, randomized controlled trial {1a}"],"prefix":"10.1186","volume":"27","author":[{"given":"Yudai","family":"Takatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masumi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Ohtsuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"9781_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jpsychores.2006.10.004","volume":"62","author":"L Michaud","year":"2007","unstructured":"Michaud L, B\u00fcla C, Berney A, Camus V, Voellinger R, Stiefel F, et al. Delirium: guidelines for general hospitals. J Psychosom Res. 2007;62:371\u201383. https:\/\/doi.org\/10.1016\/j.jpsychores.2006.10.004.","journal-title":"J Psychosom Res"},{"key":"9781_CR2","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1111\/jgs.17740","volume":"70","author":"S Lee","year":"2022","unstructured":"Lee S, Chen H, Hibino S, Miller D, Healy H, Lee JS, et al. Can we improve delirium prevention and treatment in the emergency department? A systematic review. J Am Geriatr Soc. 2022;70:1838\u201349. https:\/\/doi.org\/10.1111\/jgs.17740.","journal-title":"J Am Geriatr Soc"},{"key":"9781_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3704","volume":"341","author":"J Young","year":"2010","unstructured":"Young J, Murthy L, Westby M, Akunne A, O\u2019Mahony R, Guideline Development Group. Diagnosis, prevention, and management of delirium: summary of NICE guidance. BMJ. 2010;341:c3704. https:\/\/doi.org\/10.1136\/bmj.c3704.","journal-title":"BMJ"},{"key":"9781_CR4","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1097\/CCM.0000000000003299","volume":"46","author":"JW Devlin","year":"2018","unstructured":"Devlin JW, Skrobik Y, G\u00e9linas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical practice guidelines for the prevention and management of pain, agitation\/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46:e825\u201373. https:\/\/doi.org\/10.1097\/CCM.0000000000003299.","journal-title":"Crit Care Med"},{"key":"9781_CR5","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/S0140-6736(16)30580-3","volume":"388","author":"X Su","year":"2016","unstructured":"Su X, Meng ZT, Wu XH, Cui F, Li HL, Wang DX, et al. Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial. Lancet. 2016;388:1893\u2013902. https:\/\/doi.org\/10.1016\/S0140-6736(16)30580-3.","journal-title":"Lancet"},{"key":"9781_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12871-023-02158-1","volume":"23","author":"T Minami","year":"2023","unstructured":"Minami T, Watanabe H, Kato T, Ikeda K, Ueno K, Matsuyama A, et al. Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial). BMC Anesthesiol. 2023;23:193. https:\/\/doi.org\/10.1186\/s12871-023-02158-1.","journal-title":"BMC Anesthesiol"},{"key":"9781_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/jamapsychiatry.2013.3320","volume":"71","author":"K Hatta","year":"2014","unstructured":"Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiat. 2014;71:397\u2013403. https:\/\/doi.org\/10.1001\/jamapsychiatry.2013.3320.","journal-title":"JAMA Psychiat"},{"key":"9781_CR8","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12865","volume":"81","author":"K Hatta","year":"2019","unstructured":"Hatta K, Kishi Y, Wada K, Takeuchi T, Hashimoto N, Suda K, et al. Real-world effectiveness of ramelteon and suvorexant for delirium prevention in 948 patients with delirium risk factors. J Clin Psychiatry. 2019;81:19m12865. https:\/\/doi.org\/10.4088\/JCP.19m12865.","journal-title":"J Clin Psychiatry"},{"key":"9781_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18254","volume":"2","author":"R Rosenberg","year":"2019","unstructured":"Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a Phase 3 randomized clinical trial. JAMA Netw Open. 2019;2:e1918254. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.18254.","journal-title":"JAMA Netw Open"},{"key":"9781_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.schres.2019.07.055","volume":"215","author":"N Iwata","year":"2020","unstructured":"Iwata N, Ishigooka J, Kim WH, Yoon BH, Lin SK, Sulaiman AH, et al. Efficacy and safety of Blonanserin transdermal patch in patients with schizophrenia: a 6-week randomized, double-blind, placebo-controlled, multicenter study. Schizophr Res. 2020;215:408\u201315. https:\/\/doi.org\/10.1016\/j.schres.2019.07.055.","journal-title":"Schizophr Res"},{"key":"9781_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/YIC.0000000000000428","volume":"38","author":"K Hatta","year":"2023","unstructured":"Hatta K, Usui C, Nakamura H. Acceptability of transdermal antipsychotic patches by patients who refuse oral medication and their effectiveness in preventing recurrence of delirium: a retrospective observational study. Int Clin Psychopharmacol. 2023;38:23\u20137. https:\/\/doi.org\/10.1097\/YIC.0000000000000428.","journal-title":"Int Clin Psychopharmacol"},{"key":"9781_CR12","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1002\/phar.1563","volume":"35","author":"SE McBane","year":"2015","unstructured":"American College of Clinical Pharmacy, McBane SE, Dopp AL, Abe A, Benavides S, Chester EA, et al. Collaborative drug therapy management and comprehensive medication management-2015. Pharmacotherapy. 2015;35:e39-50. https:\/\/doi.org\/10.1002\/phar.1563.","journal-title":"Pharmacotherapy"},{"key":"9781_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40780-025-00512-8","volume":"11","author":"Y Sato","year":"2025","unstructured":"Sato Y, Takatani Y, Nakagawa S, Katada Y, Tsuchido Y, Sugimoto M, et al. Efficacy of protocol-based pharmacotherapy management in switching of antibiotic administration routes and dose adjustment based on renal function: a before\u2013after study. J Pharm Health Care Sci. 2025;11:113. https:\/\/doi.org\/10.1186\/s40780-025-00512-8.","journal-title":"J Pharm Health Care Sci"},{"key":"9781_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1176\/appi.psy.51.5.425","volume":"51","author":"M Kato","year":"2010","unstructured":"Kato M, Kishi Y, Okuyama T, Trzepacz PT, Hosaka T. Japanese version of the delirium rating scale, revised-98 (DRS-R98-J): reliability and validity. Psychosomatics. 2010;51:425\u201331. https:\/\/doi.org\/10.1176\/appi.psy.51.5.425.","journal-title":"Psychosomatics"},{"key":"9781_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/wps.20050","volume":"12","author":"DA Regier","year":"2013","unstructured":"Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: classification and criteria changes. World Psychiatry. 2013;12:92\u20138. https:\/\/doi.org\/10.1002\/wps.20050.","journal-title":"World Psychiatry"},{"key":"9781_CR16","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra052321","volume":"354","author":"SK Inouye","year":"2006","unstructured":"Inouye SK. Delirium in older persons. N Engl J Med. 2006;354:1157\u201365. https:\/\/doi.org\/10.1056\/NEJMra052321.","journal-title":"N Engl J Med"},{"key":"9781_CR17","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","volume":"71","author":"By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2023","unstructured":"By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71:2052\u201381. https:\/\/doi.org\/10.1111\/jgs.18372.","journal-title":"J Am Geriatr Soc"},{"key":"9781_CR18","doi-asserted-by":"publisher","first-page":"e970","DOI":"10.4088\/JCP.16m11194","volume":"78","author":"K Hatta","year":"2017","unstructured":"Hatta K, Kishi Y, Wada K, Takeuchi T, Ito S, Kurata A, et al. Preventive effects of suvorexant on delirium: a randomized placebo-controlled trial. J Clin Psychiatry. 2017;78:e970\u20139. https:\/\/doi.org\/10.4088\/JCP.16m11194.","journal-title":"J Clin Psychiatry"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09781-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09781-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09781-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T17:01:49Z","timestamp":1783962109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09781-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9781"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09781-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Kyoto University Hospital (approval no. Y0142). The study is conducted in accordance with the Declaration of Helsinki and the Clinical Research Act (CRA) of Japan. Because the use of blonanserin for delirium is off-label in Japan, this study is classified as a \u201cSpecified Clinical Trial\u201d under the CRA. The study protocol strictly adheres to CRA regulations to ensure data reliability and participant protection. The off-label use of blonanserin for the treatment of delirium has been approved by the institutional committee, ensuring that medical staff are familiar with its administration and safety profile. Written informed consent will be obtained from all participants. Given the emergency setting, if a participant lacks the capacity to provide consent owing to impaired consciousness or cognitive dysfunction, written informed consent will be obtained from a legally authorized representative (e.g., spouse, parent, or adult child). If the participant regains capacity, they will be informed about the study, and their consent for continued participation will be obtained. To ensure privacy, all personal information will be pseudonymized using participant ID codes. The link between the ID codes and identifiable personal information will be stored in a secure, locked location at the study site. Access to the raw data will be restricted to authorized study personnel only. All data will be maintained in accordance with the CRA and the study protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {30}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {7b}"}}],"article-number":"492"}}